ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Zhang, Xiaomin; Zhu, Lingling; Zhang, Hui; Chen, Shanshan; Xiao, Yang*广州中医药大学; 南方医科大学; y
Frontiers in Immunology2022-6-10DOI: 10.3389/fimmu.2022.927153
47被引11阅读
引用收藏
分享

摘要

Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations.

学科与关键词

关键词
CAR-T cellhematological malignanciesCAR-T related toxicitiesantigen escapeimmunosuppressive tumor microenvironmentcombinatorial therapy
相关
加载中…
  • Current state of CAR-T therapy for T-cell malignancies
    Luo, Liangkui; Zhou, Xuan; Zhou, Lijuan; Liang, Zhao; Yang, Jilong; Tu, Sanfang*; Li, Yuhua*Therapeutic Advances in Hematology, 2022, 13: 20406207221143025.被引 6
  • Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
    Xiao, Xinyi; Huang, Shengkang; Chen, Sifei; Wang, Yazhuo; Sun, Qihang; Xu, Xinjie*; Li, Yuhua*JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40(1): 367.被引 60
  • Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies
    Liu, Qianzhen; Liu, Zengping; Wan, Rongxue*; Huang, Wenhua*Cancers, 2022, 14(18): 4452.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2022-06-10
卷期
第 13 卷
页码
927153
DOI
10.3389/fimmu.2022.927153
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81973583, 81873426]; Guangdong Basic and Applied Basic Research Foundation [2021A1515011575]

作者

  • Z

    Zhang, Xiaomin (第一作者)

    guangzhou univ chinese med

  • Z

    Zhu, Lingling

    southern med univ

查看全部 5 位作者收起作者
  • Z

    Zhang, Hui

    jishou univ

  • C

    Chen, Shanshan

    southern med univ

  • X

    Xiao, Yang (通讯)

    guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417